# Pharnext

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharnext

- Industry: Pharmaceuticals
- Headquarters: Paris, France
- Website: www.pharnext.com
- Total disclosed funding: $19M
- Latest round: Series A (Feb 9, 2012)
- Investors on record: 6

## About

Founded in 2007 and based in France, Pharnext SA is a biopharmaceutical company that focuses on developing innovative drug combinations based on genomic big data and artificial intelligence for the treatment of neurological diseases. Its products include PLEODRUG PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A) and PLEODRUG PXT864 for the treatment of Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS or Charcot's disease).

## Funding rounds

- Series A, Feb 9, 2012, $9.9M — Truffle Capital, Parinvest, La Financière Gaspard
- Series A, Jun 9, 2010, $5.9M — Truffle Capital, SWEN Capital Partners, CD Capital, Aurinvest Capital
- Series A, Aug 14, 2007, $3.4M — Truffle Capital

## Investors

- Truffle Capital (https://capitalatlas.ai/funds/truffle-capital) — Series A
- SWEN Capital Partners (https://capitalatlas.ai/funds/swen-capital-partners) — Series A
- CD Capital — Series A
- Aurinvest Capital (https://capitalatlas.ai/funds/aurinvest-capital) — Series A
- Parinvest — Series A
- La Financière Gaspard (https://capitalatlas.ai/funds/la-financiere-gaspard) — Series A